Mon.Nov 18, 2024

article thumbnail

Sanofi lays out €40M to beef up transplant, diabetes drug production in France

Fierce Pharma

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in a bid to boost production for a long-approved transplant treatment and a | Sanofi has unveiled a 40 million euro investment at its Lyon Gerland biomanufacturing site in France. The cash infusion will help bolster local production of the company’s polyclonal antibody Thymoglubulin for kidney transplant rejection, as well as expected future capacity needs for the type 1 diab

article thumbnail

Market Trends to Watch for Health Systems and Their Specialty Pharmacies

MedCity News

The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients. The post Market Trends to Watch for Health Systems and Their Specialty Pharmacies appeared first on MedCity News.

Marketing 126
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Despite fears over RFK Jr. pick, industry should focus more on FDA job: analyst

Fierce Pharma

Robert F. | In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr. may not rock the boat as much as feared for the biopharma industry.

Biopharma 299
article thumbnail

Evvy Introduces Treatments for Common Vaginal Symptoms

MedCity News

Evvy has launched a new line of prescription products to relieve vaginal discomfort. The products are available on the company’s website, with prices ranging from $35 to $59. The post Evvy Introduces Treatments for Common Vaginal Symptoms appeared first on MedCity News.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ

Fierce Pharma

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters. | The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters.

288
288
article thumbnail

Tirzepatide gets a big win in obesity-related heart failure

pharmaphorum

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 receptor agonist class.The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly's drug cut the risk of cardiovascular mortality and worsening heart failure events by 38% over a median follow-up of roughly two years.

More Trending

article thumbnail

AI could 'cut ECG result wait times and speed up treatment'

pharmaphorum

Using AI-powered PanEcho software for screening ECGs could deliver results more quickly and allow treatment to be started earlier.

105
105
article thumbnail

VBI Vaccines recalls hepatitis B shot as it winds down operations

Fierce Pharma

Months after filing for bankruptcy, VBI Vaccines is taking the next step in shuttering operations with the voluntarily withdrawal of its hepatitis B vaccine, PreHevbrio. | The company initiated a voluntary recall of its sole commercial product, 2021-approved PreHevbrio, after filing for Chapter 15 bankruptcy earlier this year.

147
147
article thumbnail

Grifols linked to €7bn takeover offer from Brookfield

pharmaphorum

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company.A report in Spanish newspaper El Confidencial suggests that Brookfield is preparing to make a bid to take a 65% controlling stake in the drugmaker for €10.50 per share, worth around €7 billion ($7.4 billion).

Pharma 105
article thumbnail

AbbVie’s Elahere wins European approval for certain ovarian cancers

Pharmaceutical Technology

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Neurogene falls again on Rett gene therapy side effects

pharmaphorum

Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares

article thumbnail

How Copyright Clearance Center’s Michael Healy Advocates for ‘Responsible AI‘

Copyright Clearance Center

In a rapidly evolving publishing landscape, the executive director of the CCC is taking the lead on addressing one of the industry’s most pressing concerns: the use of copyrighted material in artificial intelligence systems.

Leads 98
article thumbnail

Syndax gets FDA okay for first-in-class leukaemia drug

pharmaphorum

Shortly after a disappointing trial readout for Syndax's menin inhibitor Revuforj in one form of leukaemia, the company has claimed FDA approval in another

FDA 104
article thumbnail

AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults

Pharmaceutical Technology

During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically diagnosed FCS,

98
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

AbbVie bags EU nod for key drug from ImmunoGen takeover

pharmaphorum

AbbVie's Elahere is approved in EU, ending a 10-year wait for a new therapy for platinum-resistant ovarian cancer.

98
article thumbnail

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

Pharmaceutical Technology

The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment of various retinal diseases.

article thumbnail

Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval

MedCity News

Approval of Syndax’s Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin. Other companies developing menin inhibitors include Kura Oncology, Biomea Fusion, and Johnson & Johnson subsidiary Janssen. The post Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval appeared first on MedCity News.

article thumbnail

FDA approves Syndax’s Revuforj to treat leukaemia

Pharmaceutical Technology

The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.

FDA 97
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

What Matters Most: The Three Trends That Will Change Pharma Marketing in 2025

Eversana Intouch

Download the Report This year’s EVERSANA INTOUCH annual trends forecast – our ninth! – is both smaller and bigger than those that have come before it. It’s smaller because while in previous years we looked at five to seven trends affecting marketers, this year we’re spotlighting only three. It’s bigger because the impact of these issues is almost impossible to overstate.

article thumbnail

Teva and Immunai partner to improve clinical decision making

PharmaTimes

The companies will focus on mechanisms of action, dose selection and biomarker analyses

article thumbnail

The first MASH drug could open the door for others — including GLP-1s

PharmaVoice

With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.

article thumbnail

Why Your Pharmacist Might Know the Best Option for You

Contrarian Sales Techniques

Have you ever gone to a pharmacy with a prescription, only to find out the medicine isn’t in stock? It’s a bit of a letdown, right? But here’s the good news: Pharmacists in Malaysia are allowed to suggest alternatives that are just as effective, and sometimes even more affordable. Let’s talk about how they do it and why it matters. What Does It Mean to Recommend an Alternative?

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

FDA Grants Rare Pediatric Disease Designation for Treatment of Neonatal SP-B Deficiency

Pharmacy Times

The disorder presents as severe lung disease, with lung transplantation as the only current therapeutic option for long-term survival.

FDA 61
article thumbnail

Sanofi investment to enhance antibody bioproduction in France

European Pharmaceutical Review

Sanofi is investing over €40 million in its Lyon Gerland site, supporting antibody bioproduction in France. A portion of this, €25 million, will be directed toward production and development of Sanofi’s second generation of its polyclonal antibody Thymoglubulin. It is used for transplantation and is manufactured exclusively at the Lyon Gerland site, Sanofi stated.

article thumbnail

Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug

PharmaVoice

Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma.

Pharma 59
article thumbnail

CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC

Pharmacy Times

Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.

58
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Why Medicines at Government Clinics Are So Affordable

Contrarian Sales Techniques

Have you noticed how government clinics can charge so little for medicines, or even give them away for free at times? If you’ve been to one, you’ve probably seen how affordable it is. But what’s the secret behind this? Let’s unpack the system that makes healthcare so accessible for Malaysians. How Does It Work? Government clinics get their medicines directly from suppliers, often in bulk, at negotiated prices.

article thumbnail

Empowering Veterans: How the VALOR-QI Program Lowers Atherosclerotic Cardiovascular Disease Risk

Pharmacy Times

Rachel Chandra, PharmD, MPH, FASHP, shares insight into the VALOR-QI program.

55
article thumbnail

Pharma Pulse 11/19/24: Behind FDA PD-1 Inhibitor Label Restrictions, Email Reminders Improve Flu Shot Rates & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 52
article thumbnail

Study Identifies Factors Influencing Quality of Life for Young Breast Cancer Survivors

Pharmacy Times

Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.

52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A